BioVersys AG has announced the publication of two Phase 1 clinical pharmacology studies of its lead antibiotic candidate BV100 in the International Journal of Antimicrobial Agents and the Journal of Antimicrobial Chemotherapy, according to a release distributed via NEWMEDIAWIRE. The data are important because they fill in key pharmacological gaps for an intravenous antibiotic intended for critically ill patients with few treatment options, and they come as the company enrolls patients in a pivotal Phase 3 registration trial.
The lung penetration study, published in the International Journal of Antimicrobial Agents (10.1016/j.ijantimicag.2026.108014), enrolled 36 healthy male participants who received intravenous rifabutin 300 mg every 12 hours for four days. Concentrations of rifabutin in lung fluid and alveolar macrophages exceeded plasma concentrations at every time point, with median penetration ratios of approximately 35-fold and over 300-fold, respectively, and repeated dosing was well tolerated. Those exposures provide a strong pharmacological rationale for further clinical evaluation of BV100 in severe pneumonia caused by carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (CRABC), a pathogen with high mortality and limited treatment options.
The drug-interaction studies, published in the Journal of Antimicrobial Chemotherapy (DOI: 10.1093/jac/dkag317), show that BV100 is a mild CYP3A inducer, reducing midazolam exposure by approximately 47%, and a mild substrate for CYP3A inhibitors, with rifabutin exposure increasing 1.3- to 1.7-fold with itraconazole. That profile is milder than that of rifampicin, a strong CYP3A inducer, and BV100 was safe and well tolerated in both studies.
The interaction findings matter because critically ill pneumonia patients typically receive many concomitant medicines, and a strong inducer can undermine the effectiveness of co-administered drugs. A milder profile could make BV100 easier to use alongside standard intensive care therapies.
Dr. Glenn Dale, Chief Development Officer of BioVersys and co-author of the publications, said the papers address the questions that matter most for an intravenous antibiotic in critically ill pneumonia patients, noting that BV100 has very good distribution in lung fluid and alveolar macrophages and a mild, manageable drug-interaction profile. Dr. Marc Gitzinger, Chief Executive Officer and founder, said carbapenem-resistant Acinetobacter baumannii represents one of the highest medical needs in infectious disease and that the data strengthen the scientific basis for BV100 therapy in CRABC pneumonia.
Both datasets form part of the clinical pharmacology foundation of RIV-TARGET, the ongoing global Phase 3 registrational trial of BV100 in hospital- and ventilator-associated bacterial pneumonia caused by CRABC. Enrollment is ongoing, with topline data anticipated in early 2028. BV100 is also being studied in the open-label Phase 2b differentiation trial, RIV-CARE, in collaboration with ADVANCE-ID. BV100 received US FDA Fast Track Designation in September 2026, under the Qualified Infectious Disease Product designation granted in 2019.
